DYNAMIC EXPANSION AND FUNCTIONAL TUNING OF NATURAL KILLER CELLS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Paulo Rodrigues-Santos, 100478

IS THE HIGH-THROUGHPUT DROPLET DIGITAL PCR A NEXT-GENERATION TECHNOLOGY FOR ACCURATE AND SENSITIVE BCR-ABL1 QUANTIFICATION FOR DEEP MOLECULAR RESPONSE MONITORING IN CML?

EHA Library, Hana Zizkova, 100479

EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND

EHA Library, Tim Hughes, 100480

ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL)

EHA Library, Tim Hughes, 100481

DEEP MOLECULAR RESPONSE TO NILOTINIB AS FIRST-LINE TREATMENT OF BCR-ABL+ CML

EHA Library, Fausto Castagnetti, 100482

SMOOTHENED (SMO) INHIBITOR LDE225 COMBINED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT (R/I) TO AT LEAST 1 PRIOR TYROSINE KINASE INHIBITOR: A PHASE 1B STUDY

EHA Library, Oliver Ottmann, 100483

FINAL LASOR RESULTS: SWITCH TO NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND SUBOPTIMAL CYTOGENETIC RESPONSE (CYR) TO FRONTLINE IMATINIB (IM)

EHA Library, Philipp Le Coutre, 100484

HEALTH-RELATED QUALITY OF LIFE IN CML PATIENTS UNDER NILOTINIB FIRST-LINE TREATMENT: RESULTS OF A GERMAN SUB-STUDY WITHIN THE ENEST1ST TRIAL

EHA Library, Insa Lütge, 100485

PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL

EHA Library, Jorge Cortes, 100486

RESPONSES AT EARLY LANDMARK TIME POINTS ARE ASSOCIATED WITH OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS (PTS) TREATED WITH PONATINIB

EHA Library, Martin Müller, 100487

LONG-TERM FOLLOW-UP OF PONATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH THE T315I MUTATION IN THE PHASE 1 AND PHASE 2 (PACE) TRIALS

EHA Library, Michele Baccarani, 100488

MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB

EHA Library, Moshe Talpaz, 100489

HYPOPLASTIC MYELODYSPLASTIC SYNDROME (H-MDS): DISTINCT CLINICO-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE

EHA Library, Chi-Yuan Yao, 100490

LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DUSSELDÖRF, AND GESMD REGISTRIES

EHA Library, Sophie Park, 100491

EVALUATION OF DYSPLASIAS IN 1979 PATIENTS WITH MYELODYSPLASTIC SYNDROMES COLLECTED IN A GERMAN-AUSTRIAN DATA SET TO APPROACH THE HETEROGENEITY OF THE DISEASE

EHA Library, Michael Pfeilstöcker, 100492

RANDOMIZED, PLACEBO (PBO)-CONTROLLED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG (EPAG) IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Uwe Platzbecker, 100493

THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS FROM THE MDS-005 TRIAL

EHA Library, Valeria Santini, 100494

IMPACT OF MDS ON HEALTH-RELATED QUALITY OF LIFE: A COMPARISON OF IPSS LOW- AND INT-1 RISK MDS PATIENTS FROM THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY AND EUROPEAN REFERENCE POPULATIONS

EHA Library, Reinhard Stauder, 100495

SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY): THE LARGEST RETROSPECTIVE STUDY OF TREATMENT WITH ESAS IN LOWER RISK MDS

EHA Library, María Díez Campelo, 100496

MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q)

EHA Library, Valeria Santini, 100497

PROGNOSTIC IMPACT OF CHROMOSOMAL TRANSLOCATIONS IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS. A STUDY BY THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROMES.

EHA Library, Meritxell Nomdedeu, 100498

SUPERIOR LONG-TERM OUTCOMES OF LOWER RISK MDS PATIENTS WHEN TRANSPLANTED IN RESPONSE COMPARED TO RELAPSED OR REFRACTORY TO HMA

EHA Library, Yoo JinLee, 100499

THE MTOR SIGNALING PATHWAY IS ACTIVIVED IN T CELLS OF APLASTIC ANEMIA

EHA Library, Guangsheng He, 100500

THE PREVALENCE OF GATA-2 MUTATION AMONG PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME IN CZECH REPUBLIC

EHA Library, Michaela Reiterová, 100501

EVALUATION OF BONE MARROW MICROVESSEL DENSITY IN PATIENTS WITH APLASTIC ANEMIA AND ITS ROLE IN PREDICTING OUTCOME TO THERAPY.

EHA Library, Somasundaram Venkatesan, 100502

IMMUNOPHENOTYPIC PROFILING OF ERYTHROID PROGENITOR-DERIVED EXTRACELLULAR VESICLES IN DIAMOND-BLACKFAN ANAEMIA: A NEW DIAGNOSTIC STRATEGY

EHA Library, Serena Macrì, 100503

ALTERATION OF HEME METABOLISM IN A CELLULAR MODEL OF DIAMOND-BLACKFAN ANEMIA

EHA Library, Deborah Chiabrando, 100504

AUTOIMMUNE NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY

EHA Library, Piero Farruggia, 100505

PRELIMINARY DATA ON THE OUTCOME OF BONE MARROW TRANSPLANTATION IN CONGENITAL DISKERATOSIS. AN ANALYSIS FROM THE EUROPEAN GROUP FOR BONE MARROW TRANSPLANTATION (EBMT).

EHA Library, Francesca Fioredda, 100506

SOLUBLE CD163 AS A MARKER FOR MACROPHAGE ACTIVATION IN CHILDREN AND ADOLESCENTS WITH GAUCHER DISEASE: RELATION TO PULMONARY AND BONE INVOLVEMENT

EHA Library, Amira AM Adly, 100507

THE PROGNOSIS OF ACQUIRED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADULTS IS HEAVILY AFFECTED BY A COEXISTING VIRAL INFECTION: ANALYSIS OF A SINGLE INSTITUTION SERIES OF 35 PATIENTS

EHA Library, Chiara Cattaneo, 100508

A COMPREHENSIVE GENOME-WIDE COPY NUMBER ALTERATIONS (CNAS) ANALYSIS OF HOMOGENEOUSLY TREATED, NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS.

EHA Library, Carolina Terragna, 100509

RELATIONSHIP BETWEEN INHIBITION PROFILE OF Β1, Β2 AND Β5 PROTEASOME SUBUNITS AND CYTOTOXIC ACTIVITY OF PROTEASOME INHIBITORS IN MULTIPLE MYELOMA

EHA Library, Andrej Besse, 100510

S1P MODULATOR FTY720 TARGETS OSTEOCLASTOGENESIS IN CXCR4-BASED MULTIPLE MYELOMA SYSTEMIC XENOGRAFT MODEL

EHA Library, Katia Beider, 100511

PTC-209, A TRANSCRIPTIONAL SMALL MOLECULE INHIBITOR OF BMI-1, DEMONSTRATES POTENT ANTI-MYELOMA ACTIVITY IN VITRO

EHA Library, Arnold Bolomsky, 100512

POMALIDOMIDE ENHANCES THE ACTIVATION OF ANTI-MYELOMA SPECIFIC T CELLS IN HEALTHY DONORS AND MULTIPLE MYELOMA PATIENTS

EHA Library, Jingying Dai, 100513

LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES.

EHA Library, Federica Costa, 100514

P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS

EHA Library, Maria Teresa Fulciniti, 100515

BONE MARROW-MEDIATED DRUG RESISTANCE IS PROMOTED BY JAGGED-INDUCED NOTCH PATHWAY IN MULTIPLE MYELOMA

EHA Library, Silvia Garavelli, 100516

FDG-PET/CT FOCAL LESIONS IN THE ABSENCE OF OSTEOLYSES AS A NEW MARKER OF PROGRESSION OF SMOLDERING MULTIPLE MYELOMA INTO SYMPTOMATIC DISEASE

EHA Library, Elena Zamagni, 100517

ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE

EHA Library, Philippe Moreau, 100518

WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)

EHA Library, James Berenson, 100519

EARLY MORTALITY IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS OF TWO LARGE RANDOMIZED PHASE III TRIALS

EHA Library, Alessandra Larocca, 100520

MAINTENANCE THERAPY WITH LENALIDOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE EMN01 TRIAL.

EHA Library, Valeria Magarotto, 100521

OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY

EHA Library, Antonio Palumbo, 100522

THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 100523

IMPACT OF RENAL IMPAIRMENT ON OUTCOMES AFTER TREATMENT WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FIRST TRIAL RESULTS

EHA Library, Meletios Dimopoulos, 100524

AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE AND WITH BACKBONE REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Maria Victoria Mateos, 100525

OUTCOMES OF PATIENTS WITH PRIMARY REFRACTORY MULTIPLE MYELOMA IN THE ERA OF NOVEL THERAPIES

EHA Library, Neil Majithia, 100526

ASSESSING THE BENEFIT OF CONTINUOUS TREATMENT IN THE FIRST TRIAL (MM-020): IMPACT OF RESPONSE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Nizar J Bahlis, 100527

LACK OF RESPONSE IMPROVEMENT BEYOND DAY +100 AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN ABSENCE OF MAINTENANCE THERAPY IN MULTIPLE MYELOMA

EHA Library, Carlos Fernandez Delarrea, 100528

RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS

EHA Library, Noopur Raje, 100529

PROGRESSION-FREE SURVIVAL 2 (PFS2) IS THE MOST SIGNIFICANT PROGNOSTIC FACTOR OF LONG-TERM SURVIVAL IN THE ERA OF NOVEL AGENTS: A SINGLE GREEK MYELOMA CENTER EXPERIENCE.

EHA Library, Eirini Katodritou, 100530

OBESITY AND RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A POPULATION-BASED STUDY

EHA Library, Marianna Thordardottir, 100531

POST AUTOLOGOUS STEM CELL TRANSPLANTATION MAINTENANCE IN MULTIPLE MYELOMA. SINGLE CENTER EXPERIENCE OF 18 YEARS: A MARKED SURVIVAL ADVANTAGE WITH INTERFERON.

EHA Library, Gergely Varga, 100532

WHOLE BODY DIFFUSION WEIGHTED MRI SCANNING IN PATIENTS WITH MYELOMA. INCIDENTAL FINDINGS - THE ROYAL MARSDEN EXPERIENCE.

EHA Library, Charlotte PAWLYN, 100533

PATTERNS OF TOTAL COST OF CARE BY AGE GROUP FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

EHA Library, Steven Arikian, 100534

ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE 1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA

EHA Library, Valeria Magarotto, 100535

ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010)

EHA Library, Katja Weisel, 100536

PROGNOSTIC VALUE AND USEFULNESS OF SERUM-FREE-LIGHT-CHAINS-RATIO (SFLCR) AND SERUM HEAVY-LIGHT-CHAINS-RATIO (SHLCR) IN SYMPTOMATIC MULTIPLE MYELOMA IN THE CONTEXT OF THREE GEM/PETHEMA CLINICAL TRIALS

EHA Library, Lucia Lopez-Anglada Fernandez, 100537

VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA : PHASE 1B RESULTS

EHA Library, Philippe Moreau, 100538

RETROSPECTIVE REFINING OF DIAGNOSIS IN 286 MGUS AND SMM PATIENTS ACCORDING TO THE UPDATED IMWG CRITERIA. CLINICAL IMPLICATIONS

EHA Library, Eftychia Nikolaou, 100539

IS A DEEP RESPONSE THE KEY TO SUCCESSFUL TREATMENT OF MULTIPLE MYELOMA?

EHA Library, Johan Liwing, 100540

FAMILY HISTORY OF LYMPHOPROLIFERATIVE DISEASE ASSOCIATED WITH A SUPERIOR SURVIVAL IN MULTIPLE MYELOMA: A POPULATION-BASED STUDY

EHA Library, Kristrún Aradóttir, 100541

PARENTAL LONGEVITY AND SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA AND MGUS.

EHA Library, Ingigerdur Sverrisdottir, 100542

SERUM B-CELL MATURATION ANTIGEN IS A NOVEL PROGNOSTIC INDICATOR FOR MULTIPLE MYELOMA PATIENTS AND CORRELATES WITH CLINICAL STATUS AND SURVIVAL

EHA Library, James Berenson, 100543

THE NOTCH LIGANDS JAGGED1 AND 2 ARE A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA-ASSOCIATED BONE DISEASE

EHA Library, Michela Colombo, 100544

CRITICAL ROLE OF HIS499 IN REGULATING THE DIMERIZATION AND FUNCTION OF THE HUMANTHROMBOPOIETIN RECEPTOR AND RESTRAINING THE REPERTOIRE OF ASPARAGINE PATHOGENICMUTATIONS.

EHA Library, Emilie Leroy, 100545

COMBINED CONSTITUTIVE CANONICAL AND NON-CANONICAL HH SIGNALING CAUSED BY DEPLETION OF PATCHED 2 INDUCES A MYELOPROLIFERATIVE PHENOTYPE AND TRANSFORMS CHRONIC MPNS INTO ACUTE LEUKEMIAS

EHA Library, Claudius Klein, 100546

HIGH RESOLUTION CYTOGENETIC MAPPING AND WHOLE EXOME SEQUENCING REVEAL A COMPLEX PATTERN OF CHROMOSOME 6P ABERRATIONS IN PATIENTS WITH MYELOID MALIGNANCIES

EHA Library, Ana Pudja, 100547

DNA METHYLATION PROFILING OF SORTED CELLS FROM MYELOFIBROSIS PATIENTS REVEALS ABERRANT EPIGENETIC REGULATION OF IMMUNE PATHWAYS AND IDENTIFIES EARLY MPN DRIVER GENES

EHA Library, Helene Myrtue Nielsen, 100548

NDEL1-PDGFRB FUSION GENE IN JUVENILE MYELOMONOCYTIC LEUKEMIA ASSOCIATED WITH RESISTANCE TO TYROSINE KINASE INHIBITORS

EHA Library, Konstantin Byrgazov, 100549

IDENTIFICATION AND CHARACTERIZATION OF PUTATIVE NEOPLASTIC STEM CELLS IN PATIENTS WITH MAST CELL LEUKEMIA

EHA Library, Gregor Eisenwort, 100550

COMORBIDITY AND ITS IMPACT ON ALL-CAUSE MORTALITY IN DANISH PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS FROM 1994-2013: A POPULATION-BASED MATCHED COHORT STUDY

EHA Library, Marie Bak, 100551

IMPACT OF JAK2, CALR OR MPL MUTATION STATUS ON PREGNANCY OUTCOME IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA

EHA Library, Elisa Rumi, 100552

QUALITY OF LIFE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS COMPARED TO NORMAL INDIVIDUALS – CASE-CONTROL EVIDENCE OF SIGNIFICANT IMPAIRMENT

EHA Library, Andrew Duncombe, 100553

PREDICTORS OF SURVIVAL IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Danijela Lekovic, 100554

ELEVATED HEMOGLOBIN CONCENTRATION AND RISK OF ACUTE MYOCARDIAL INFARCTION AND VENOUS THROMBOEMBOLISM

EHA Library, Malin Hultcrantz, 100555

IMPACT OF DYNAMIC BLOOD COUNT FOLLOW-UP ON VASCULAR COMPLICATIONS IN 217 PV PATIENTS

EHA Library, Anneli Enblom, 100556

SPLEEN ENLARGEMENT IS A RISK FACTOR FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: EVALUATION ON 1097 PATIENTS AND VALIDATION ON 792 PATIENTS

EHA Library, ALESSANDRO ANDRIANI, 100557

CLINICAL VALUE OF SPLENIC VOLUME MEASURED BY COMPUTED TOMOGRAPHY AS A NOVEL PROGNOSTIC FACTOR IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Moo-Kon Song, 100558

DYNAMIC ROLE OF THE IRF4-PU.1 AXIS IN IBRUTINIB-RESISTANT WALDENSTRÖMS MACROGLOBULINEMIA

EHA Library, Kasyapa Chitta, 100560

MICRORNA 203 CONTROLS T-CELL LYMPHOMAGENESIS BY TARGETING IL-2 RECEPTOR SIGNALING

EHA Library, Fazila Asmar, 100561

ANALYSIS OF MECHANISMS OF MALIGNANT TRANSFORMATION IN TP53 WILD-TYPE BURKITT´S LYMPHOMA BY INTEGRATION OF MOLECULAR AND FUNCTIONAL GENOMICS DATA

EHA Library, Jennifer Hüllein, 100562

COMBINED 3D IMMUNO-FISH ANALYSIS OF PRIMARY HODGKIN (H) AND REED-STERNBERG (RS) CELLS REVEALS DISRUPTION OF TELOMERE-TRF2 INTERACTION AND IDENTIFIES HODGKIN’S LYMPHOMA SHELTERIN ASSOCIATED DISEASE

EHA Library, Hans Knecht, 100563

A NOVEL ULTRA-DEEP SEQUENCING METHOD FOR TRACKING OF DRIVER MUTATIONS IDENTIFIES THE MYD88 L265P MUTATION IN EARLY HAEMOPOIETIC PRECURSORS IN DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Dipti Talaulikar, 100564

TRANSLOCATIONS AND CLONALITY DETECTION IN LYMPHOPROLIFERATIVE DISORDERS BY CAPTURE-BASED NEXT-GENERATION SEQUENCING. A PILOT STUDY BY THE EUROCLONALITY-NGS CONSORTIUM.

EHA Library, David Gonzalez, 100565

MORAXELLA CATARRHALIS – A BACTERIAL INVOLVEMENT IN THE ORIGIN OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA OF IGD TYPE?

EHA Library, Lorenz Thurner, 100566

COMBINED CHEMOIMMUNOTHERAPY (R-CVP) IS AN EFFECTIVE TREATMENT FOR HIV-NEGATIVE, HHV-8 POSITIVE PATIENTS WITH MULTICENTRIC CASTLEMAN’S DISEASE

EHA Library, Alberto Fragasso, 100567

SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER’S SYNDROME

EHA Library, Toby Eyre, 100568

A PHASE 1 TRIAL OF CUDC-907, AN ORAL, FIRST-IN-CLASS, DUAL INHIBITOR OF HDAC AND PI3K, IN PATIENTS WITH REFRACTORY OR RELAPSED LYMPHOMA AND MULTIPLE MYELOMA

EHA Library, Yasuhiro Oki, 100569

A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)

EHA Library, Moshe Talpaz, 100570

UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND HIGH-RISK CLL

EHA Library, Matthew A.Lunning, 100571

BENDAMUSTINE COMBINED WITH RITUXIMAB (BR) IN ELDERLY FRAIL PATIENTS WITH NEWLY DIAGNOSED DLBCL

EHA Library, Sergio Storti, 100572

CD56 NEGATIVE EXTRANODAL NK/T CELL LYMPHOMA SHOULD BE REGARDED AS A DISTINCT SUBTYPE WITH POOR PROGNOSIS

EHA Library, Liang Wang, 100575

DEFINING IMMUNOGLOBULIN SOMATIC HYPERMUTATION IN DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: POTENTIAL APPLICATION FOR PROGNOSIS AND RISK STRATIFICATION

EHA Library, Ilan Kirsch, 100576

A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)

EHA Library, Moshe Talpaz, 100577

ROUTINE BONE MARROW BIOPSY IN PET/TC ERA FOR HODGKIN LYMPHOMA STAGING.

EHA Library, Lopez Oreja Irene, 100578

THE PROGNOSTIC VALUE OF BIOLOGICAL MARKERS IN PEDIATRIC HODGKIN LYMPHOMA

EHA Library, Piero Farruggia, 100579

SUPPORTIVE CARE AND INFECTIOUS COMPLICATIONS IN CORD BLOOD AND HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULTS WITH HIGH RISK HEMATOLOGIC DISEASES.

EHA Library, Jean El Cheikh, 100580